{
  "name" : "zero.sci-hub.se_5573_63822ea593d3a6cb2e998d00fb61996f_qiao2015.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "A General Strategy for Facile Synthesis and In Situ Screening of SelfAssembled PolymerPeptide Nanomaterials",
    "authors" : [ "Zeng-Ying Qiao", "Chun-Yuan Hou", "Sheng-Lin Qiao", "Hao Wang" ],
    "emails" : [ "wanghao@nanoctr.cn" ],
    "sections" : [ {
      "heading" : null,
      "text" : "© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 1859wileyonlinelibrary.com\nC O M M U N IC A TIO N"
    }, {
      "heading" : "A General Strategy for Facile Synthesis and In",
      "text" : ""
    }, {
      "heading" : "Situ Screening of Self-Assembled Polymer-Peptide",
      "text" : ""
    }, {
      "heading" : "Nanomaterials",
      "text" : ""
    }, {
      "heading" : "Zeng-Ying Qiao , Yao-Xin Lin , Wen-Jia Lai , Chun-Yuan Hou , Yi Wang , Sheng-Lin Qiao ,",
      "text" : ""
    }, {
      "heading" : "Di Zhang , Qiao-Jun Fang , and Hao Wang*",
      "text" : "Dr. Z.-Y. Qiao, Y.-X. Lin, Dr. W.-J. Lai, C.-Y. Hou, Y. Wang, S.-L. Qiao, D. Zhang, Prof. Q.-J. Fang, Prof. H. Wang Laboratory for Biological Effects of Nanomaterials and Nanosafety National Center for Nanoscience and Technology (NCNST) No. 11 Beiyitiao, Zhongguancun Beijing 100190 , China E-mail: wanghao@nanoctr.cn\nDOI: 10.1002/adma.201504564\nprocedures were not suitable for peptide nanomaterial synthesis, which may cause peptide denaturation and affect their biological properties. Furthermore, the present methods for PPCs synthesis focus on the post-modifi cation, [ 13b ] but there are few reports [ 7b ] about the immediate polymerization and selfassembly of peptide that is one of the most facile approaches for construction of peptide nanosystems. Therefore, a general and simple synthesis strategy is required for polymer-peptide based nanomaterial synthesis and screening.\nHere, we fi rst report a general strategy for facile synthesis and in situ screening of a library of self-assembled PPCs. For peptides with different reactive groups, various synthesis methods based on Michael-type addition were developed. The mild and effi cient reaction with nearly quantitative yields in aqueous solutions allowed the minimal loss of peptide activity and direct biological performance measurements without purifi cation. Targeting and therapeutic peptides as model functional peptides were copolymerized with a wide variety of spacers, to obtain a diverse library of PPCs with different chemical structures, which simultaneously self-assembled into nanoparticles in the reaction process. Subsequently, the in situ cell-based screening of PPCs was used to quickly assess the therapeutic performance of PPCs. Owing to the strategy that revealed the relationship between structural features of PPCs (peptide ratio, spacer length, degree of polymerization (DP), modifi cation degree (MD), etc.) and their functions, we can somewhat predictably design and prepare PPCs with desired properties. The enhanced tumor treatment effi cacies of PPCs compared with free peptides were verifi ed in vitro and in vivo. We envision that this synthesis and screening approach provides an avenue for rapid preparation and optimization of polymer-peptide nanomaterials for different purposes.\nIn order to realize the polymerization of peptides, various synthesis methods based on Michael-type addition were developed. [ 17 ] For peptides without side amine groups, two approaches were explored for synthesis of PPCs. The one is to modify a glycine at N-terminal of peptide to obtain amine terminal peptide, and glycine and peptide GGG were used as model peptides (Schemes S1a and S2, Figures S1–S3, Supporting Information). Because glycine carries no substituents in α position, both protons in amine groups can react with diacrylate or bisacrylamide groups under the suitable conditions ( Scheme 1 a-i and Tables S1–S3, Supporting Information). The other one is modifying a cysteine in peptide chains (called amine/thiol peptide), and peptide glutathione (GSH) was\nSynthetic biomaterials based on the bioactive molecules, such as polysaccharides, [ 1 ] nucleic acids, [ 2 ] peptides, [ 3 ] and proteins, [ 4 ] have been paid extensive attention owing to their clinical translational potential. Among them, peptides with diverse biological functions are involved in a variety of physiological activities, playing an important role in modulating cell fates and tissue functions. [ 3b , 5 ] Natural peptides show minor immune responses and low toxic side effects compared to conventional chemoth erapeutics. [ 5c , 6 ] However, the applications of peptides as biopharmaceuticals or biodrugs are limited due to their poor bioavailability, low chemical stability, or short half-life in the blood circulation. To circumvent this situation, variable approaches have been demonstrated to make them more applicable and reliable, for instance, chemical modifi cation, [ 7 ] sequence mutation, [ 8 ] self-assembly, [ 9 ] and so on. Recently, peptide-based nanostructures have been successfully employed for tumor therapy, [ 10 ] tissue engineering or regenerative medicine, [ 11 ] etc. [ 12 ] Interestingly, researchers constructed polymer-peptide conjugates (PPCs) with long circulation time for tumor targeted delivery and enhanced therapeutic effi cacy. [ 13 ] Our groups also focused on the self-assembled peptide nanomaterials for cancer diagnostics [ 14 ] and therapeutics. [ 15 ] However, the key challenges in PPCs development are the multistep syntheses, nanoscaled formulation, complicated purifi cation, and distinct characterization prior to evaluation of their performance. The traditional “synthesis-purifi cation-bioassay” strategy leads to the low effi ciency, tedious chemical synthesis, time assumption, and expensiveness.\nRecently, the combinatorial synthesis and high-throughput screening approach were explored for discovering effi cient polymeric nanomaterials for gene delivery and bacterial attachment resistance. [ 16 ] Through this method, a large library of polymers with various chemical structures was prepared. However, the use of organic solvents in their reactions and post-purifi cation\nAdv. Mater. 2016, 28, 1859–1867\n1860 wileyonlinelibrary.com © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nC O\nM M\nU N\nIC A TI\nO N\nAdv. Mater. 2016, 28, 1859–1867\nScheme 1. a) The synthesis route of PPCs based on Michael-type addition (effi cient, mild, free of purifi cation) with the peptides in main chains (MC), side chains (SC), hyperbranched chains (HC), and dendrimers (DM). i–iv represent four reaction routes. The reactive groups in spacers and peptides were highlighted by blue and yellow background, respectively. b) The chemical structures of monomers ( A–D ) for MC-PPC synthesis, linear precursor polymers ( E–I ) for SC-PPC synthesis, hyperbranched precursor polymers ( J , K ) for HC-PPC synthesis, and precursor dendrimers ( L ) for DM-PPC synthesis. c) The general procedure for synthesis and in situ screening of PPC library. (1) Addition of targeting peptide (RGD), therapeutic peptide (KLAK), and spacers ( A – L ) solutions (pH 7.4/8 PBS) by pipette into a 96-well plate. (2) The synthesis of PPC was performed in enclosed 96-well plate under N 2 protection at 37 °C, and nanoparticles were in situ formed during the reaction process. (3) The PPC nanoparticle solutions were evaluated by U87 cell cytotoxicity without further purifi cation, and nanoparticles with high anticancer activity were screened effi ciently.\n1861wileyonlinelibrary.com© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nC O M M U N IC A TIO N utilized as a model peptide (Schemes S1b and S3, Figure S4, Supporting Information). For α-substituted amino acids, the reactivity of the second proton in amine group is much lower than that of the primary proton. In addition, the reactivity of thiol group is much higher than that of amine group due to easier nucleophilic addition onto diacrylate or bisacrylamide group. Therefore, thiol group and the primary proton in amine group can involve the reaction by adding the suitable catalyst, yielding the linear copolymers (Scheme 1 a-ii and Table S4, Supporting Information).\nFor a part of functional peptides, lysine is usually involved in the peptide chains to exert relevant function, so the approach for peptide with side amine groups must be explored. The PPCs with different morphologies were synthesized by two methods. For synthesis of PPCs with main chain type, two cysteines were modifi ed onto one end of the peptide, to produce peptide with two thiol groups (di-thiol peptide, Scheme S1c, Supporting Information). The model molecule dithiothreitol (DTT) was fi rst used for testing the reaction condition (Scheme S4, Figure S5, Supporting Information). The two thiols with much higher reactivity than amine groups could react with diacrylate or bisacrylamide groups to form linear polymers (Scheme 1 a-iii). The model peptide CCGGGK was utilized for obtaining the optimal synthesis conditions (37 °C, pH 7.4 PBS for diacrylate and 37 °C, pH 8.0 PBS for bisacrylamide), in which two thiols instead of amine groups were involved in the reaction (Scheme S5, Supporting Information). The chemical structure of polymeric CCGGGK was confi rmed by 1 H NMR spectra (Figures S6 and S7, Supporting Information). The broaden peaks of CH 2 linked with thiols (peak 1′) indicated the linkage of thiols onto polymer chains, while the peak of CH 2 linked with amine groups (peak 9) was still sharp, implying no reaction occurring of amine groups (Figure S6, Supporting Information). For PPCs with other morphologies such as side chain (SC), hyperbranched and dendrimer (DM) type, one cysteine was linked onto peptide (Scheme 1 a-iv). The similar reaction conditions that were pH 7.4 PBS for acrylate and pH 8.0 PBS for acrylamide were tried using GSH as a model peptide to control the linkage of thiol with different polymers (Schemes S1d and S6, Supporting Information). The 1 H NMR spectra of GSH-modifi ed poly(vinyl alcohol) (PVA-GSH) indicated that the thiol was attached onto polymer chains specifi cally due to the broaden peak of CH 2 linked with thiol (peak 5) and still sharp peak of CH 2 linked with amine (peak 1, Figure S8, Supporting Information). The effi cient synthesis was verifi ed by the disappearance of proton peak in acrylate, and the total reaction of GSH with acrylamide modifi ed chitosan was also realized (Figure S9, Supporting Information). All the model experiments proved the feasibility of PPC synthesis in mild and aqueous condition with high effi ciency and without post-purifi cation, which provided the probability for rapid synthesis and screening of a library of PPC nanomaterials.\nAfter the establishment of synthesis method of PPCs, functional peptides were introduced into polymerization for therapeutic PPC screening. The peptide RGD is well-known as a targeting molecule to bind preferentially to the α v β 3 integrin which is overexpressed on some tumor cell surfaces. [ 18 ] KLAK peptide has been developed as a therapeutic peptide by disruption of mitochondrion, inducing the cell death. [ 9a , 19 ] However,\nthe IC 50 values of free KLAK peptide toward tumor cells are high due to the ineffi cient entrance into cells. Therefore, we envisioned that the copolymerization of RGD and KLAK may elevate the ability of killing tumor cells (Scheme S7a, Supporting Information). CCGGGRGD and CCGGG(KLAKLAK) 2 were designed for synthesis of PPCs with the peptides in main chains (MC-PPC), where diacrylate or bisacrylamide ( A – D ) were used as spacers (Scheme 1 b, and Scheme S8, Figures S10 and S11, Supporting Information). CGGGRGD and CGGG(KLAKLAK) 2 were applied for linking with polymer carriers E–L that were fi rst modifi ed by acrylate or acrylamide with different modifi cation degrees (Figures S8, S9, S12–S15, Supporting Information), where E–I , J–K , and L were precursor polymers for synthesis of PPC with peptides in SC, hyperbranched chains (HC), and DM, respectively (Scheme S9 and Figure S16, Supporting Information). As shown in Scheme S7b (Supporting Information), the feed molar ratios of RGD and KLAK were adjusted to obtain polymers with various peptide ratios. The syntheses were performed by adding targeting peptide RGD, therapeutic peptide KLAK, and A – L spacers into a 96-well plate (Scheme 1 c). The combinatorial library, including >1000 PPCs with various chemical compositions, was established by changing the peptide ratios, spacers, DP and MD, and the typical PPCs were named in Tables S5 and S6 (Supporting Information). After rapid and high-content synthesis of PPCs, the PPC aqueous solutions were not further purifi ed and immediately added into cell-seeded 96-well plates for the assay of cell viability. The peptides CCGGGK and GSH were utilized as control peptide for synthesis of control polymers with different morphologies. As an initial screening, we evaluated the human primary glioblastoma (U87) cell viability of PPCs at various concentrations, and the hit PPCs with low viability were selected for further study ( Figure 1 a and Figures S17–S20, Supporting Information). The IC 50 values of PPCs were also calculated, proving that most PPCs exhibited lower IC 50 values and higher antitumor effi ciency than that of free peptides at the same molar ratios of peptide, especially for PPCs with A , E , H , and L spacers with IC 50 < 150 × 10 −6 M (Figure 1 b and Figure S21a, Table S7, Supporting Information). For peptide ratios, larger fraction of KLAK peptide in PPC is benefi cial for lowering the IC 50 values, so peptide ratios of 9 , 10 , and 11 were used for further comparison. At the same peptide concentration of 100 × 10 −6 M , the cell viability results showed that PPCs with A and E spacers still could kill U87 cells effi ciently, while other PPCs displayed lower antitumor ability (Figure 1 c). Therefore, according to this strategy, PPCs with PEG and PVA spacers were screened rapidly as potential hit PPCs for cancer therapy.\nThe advantage of this strategy for rapid screening of PPC library is the possibility of exploring the relationship of chemical structure with biological properties, which greatly help us rationally design and synthesize PPCs with optimal functions ( Figure 2 a). For MC-PPCs, DP exhibits important infl uence on the IC 50 of PPC that becomes lower as the DP value increased (Figure 2 b and Figure S22a,b, Supporting Information). It was reasonable because more functional peptides were linked on a polymer chain for PPC with high DP, which facilitated the entrance of peptide to exert impact on cellular functions. The spacer length is another important factor for PPCs with PEG\nAdv. Mater. 2016, 28, 1859–1867\n1862 wileyonlinelibrary.com © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nC O\nM M\nU N\nIC A TI\nO N\nspacers ( A – C , Figure 2 c and Figure S22c,d, Supporting Information). As the PEG spacer became shorter, the IC 50 values of PPCs decreased, which may be attributed to the shielding of long PEG chain, preventing their effi cient entrance into cells. According to these rules, PPC ( A9-3 ) with shorter PEG and higher DP was designed, and the IC 50 value decreased to ≈30 × 10 −6 M (Figure 2 d). Similar with MC-PPCs, the molecular weight has signifi cant impact on function of SC-PPCs. For PPCs with PVA spacers ( E – G ), the IC 50 value became lower while PVA chain was longer at the same modifi cation molar ratio of 5%, which could be attributed to the larger number of peptides in longer PVA chains (Figure 2 e). When the ratio was elevated to 17%, the difference was reduced (Figure S23a, Supporting Information). Meanwhile, the infl uence of MD was also important for IC 50 of PPCs. For E – G series, the IC 50 values of PPCs with MD of 17% were lower than that with MD of 5% at the same PVA molecular weight (Figure 2 f and Figure S23b,c, Supporting Information). The similar phenomena were also discovered in other PPCs (Figure S23d, Supporting Information). We speculated that larger molecular weight and higher modifi cation degree were benefi cial for enhancing the anticancer effi ciency of PPCs, so G-3 with modifi cation ratio of 33% was synthesized. However, the IC 50 values of G-3 were similar to that of G-2 , proving that the further increase of peptides in polymer chains was ineffi cient for enhancing their functions when enough peptides were linked onto chains, which also explained the reduced difference of IC 50 values for E – G PPCs with modifi cation ratio of 17%. The PPCs with different peptide ratios of 8 , 9 , and 10 were applied for IC 50 comparison, following the similar principles, which verifi ed that chemical structures of polymer backbones exerted major effect on their biological function when peptide compositions were the same. Another advantage of this synthesis method is immediate self-assembly of polymer chains during the reaction process, [ 20 ] which avoids the general complicated formulation of nanomaterials. As we know, the properties of nanomaterials are related with their aggregation morphology, size, surface potential, etc. [ 21 ] Therefore, the self-assembled behaviors of PPCs were investigated by transmission electron microscopy (TEM), and spherical aggregates were observed for all the PPCs with\nAdv. Mater. 2016, 28, 1859–1867\nFigure 1. In vitro screening of a PPC library by cell viability. a) The U87 cell viability of PPCs at different peptide concentrations by CCK-8 assay. For every PPC series except for J , the peptide concentrations from left to right are 10, 100, 250, 500, 750, 1000 × 10 −6 M . For J series, the peptide concentrations from left to right are 10, 50, 100, 250, 375, 500 × 10 −6 M . b) The comparison of IC 50 values of PPCs and free peptides. 1 – 11 represent the different peptide ratios as shown in Scheme S7b (Supporting Information), and 0 means the control polymers without functional peptides. A – L represent the different polymer carriers as shown in Scheme 1 b, and Pep row means the free peptides with various molar ratios. The A , B , and C rows are polymers with DP around 5 ( A-2 , B-2 , and C-2 ). The D rows are polymers with DP around 3 ( D-2 ). The E , H , and L rows are polymers with MD of 17% ( E-2 ), 96% ( H-3 ), and 58% ( L-3 ), respectively. c) U87 cell viability of PPCs with different structures at peptide concentration of 100 × 10 −6 M measured by CCK-8 assay. The peptide ratio of RGD:KLAK is 20:80 ( 9 ), 10:90 ( 10 ), and 0:100 ( 11 ), respectively. All the experiments were performed in triplicate, and the mean values and error bars were calculated accordingly.\n1863wileyonlinelibrary.com© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nC O M M U N IC A TIO N\nAdv. Mater. 2016, 28, 1859–1867\nFigure 2. a) The scheme of chemical structures of MC/SC/HC/DM-PPCs, and the relationship between IC 50 and chemical structure of PPCs. b) The IC 50 values comparison of B series with different DP values of 2, 5, and 7 measured in U87 cells. c) The IC 50 values comparison of A , B , and C series with the similar DP around 5 measured in U87 cells. d) The IC 50 values comparison of A series with different DP values of 5 and 7 measured in U87 cells. e) The IC 50 values comparison of E , F , and G series with the same MR of 5% measured in U87 cells. f) The IC 50 values comparison of G series with different MR values of 5%, 17%, and 33% measured in U87 cells. g) The IC 50 values comparison of A-3 (DP = 7) and G-2 (MD = 17%) series measured in MCF-7 cells. The 8 , 9 , 10 , and 11 in fi gures mean the peptide ratios of RGD and KLAK shown in Scheme S7b (Supporting Information). Results are presented as the mean ± SD in triplicate. TEM images of h) A9-3 and i) G9-3 nanoparticles in PBS solution at 37 °C with peptide concentration of 200 × 10 −6 M . j) Zeta potential of A9-3 , B9-3 , C9-3 , E9-2 , F9-2 , and G9-2 nanoparticles (peptide concentration: 500 × 10 −6 M ) in PBS solutions (pH 7.4).\n1864 wileyonlinelibrary.com © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nC O\nM M\nU N\nIC A TI\nO N diameters of 20–90 nm that is suitable for stable circulation in\nblood and effective entrance into tumor cells (Figure 2 h,i and Figure S24, Supporting Information). [ 21a , 22 ] Both dynamic light scattering (DLS) and TEM results indicated that larger nanoparticles were formed by decreasing the length of PEG spacers ( A – C PPCs) and increasing the molecular weight of polymer backbones ( E – G PPCs) (Figure S25, Supporting Information). However, the minor size difference could not affect the function of PPCs apparently. In addition, the positive zeta potentials of PPC nanoparticles were measured, which could be attributed to the positive charge of peptide RGD and KLAK. By comparing the PPCs with PEG spacers, the potential values decreased as the PEG chains became longer, but the similar values were measured for PPCs with PVA chains (Figure 2 j). We speculated that the diversity of PPC surface potentials have important infl uence on peptide RGD functions that determined the cell selectivity. The high positive potential of PPCs with PVA spacers may shield the targeting ability of RGD, resulting in the ineffi cient assistance of RGD for entering cells, so IC 50 values decreased as the KLAK peptide increased (Figure 2 f). Meanwhile, the shielding effect of PEG chains could decrease the positive potentials of PPCs, causing the exertion of RGD targeting. Therefore, the PPCs ( A series) with RGD and KLAK of certain ratios exhibit higher ability of killing U87 cells than that with 100% KLAK (Figure 2 d). The phenomena were more obvious for PPC with longer PEG chains ( B and C series), owing to the stronger shielding of PEG (Figure S21, Supporting Information). The MCF-7 cell viability assay illustrated that the IC 50 values of A-3 and G-2 decreased as the KLAK ratio increased, which was reasonable due to the lack of overexpressed α v β 3 integrin for MCF-7 cells, further confi rming the above deductions (Figure 2 g). Therefore, we believe that the chemical structure and peptide composition are the major factors for impacting on the biological functions of PPCs, while the surface potentials have infl uence on the targeting ability of RGD and cell selectivity. To further develop the PPC system, the cyclic RGD with more effective targeting ability was also applied to obtain more effi cient PPC nanodrugs (Table S8, Supporting Information), indicating that this strategy was general and could be expanded to other peptides.\nAccording to this nanomaterials synthesis and screening strategy, the guideline of structure and function was established, and hence optimal PPC with low IC 50 and high cell selectivity was obtained. In order to meet the requirement of further biological evaluation, the amount of lead PPC must be enhanced. Using the same synthesis method, we could gain similar PPC in microscale and constant reaction. Due to the reliability and scalability of this strategy, the lead A9-3 could be further evaluated in vitro and in vivo. KLAK peptide has been reported to kill cancer cells by disrupting mitochondrial membranes, [ 19b ] so JC-1 assay was applied for studying the process of cell apoptosis by confocal laser scanning microscope (CLSM, Figure 3 a). [ 23 ] Compared with free peptide Pep9 (RGD:KLAK = 2:8) and control polymer A0 without obvious cytotoxicity, A9-3 nanoparticles could destroy mitochondria seriously according to the disappearance of red fl uorescence and the increase of green fl uorescence. The apoptosis-inducing ability of A9-3 nanoparticles was analyzed by fl uorescence-activated cell sorting (FACS) that was concentration-dependent (Figure 3 b and Figure S26,\nSupporting Information). [ 24 ] At the same peptide concentration of 100 × 10 −6 M , the percentage of viable cells of A9-3 (21.5%) treated group was much lower than that of free peptide Pep9 (79.1%) and control polymer A0 (85.1%) treated cells. The similar phenomena were also observed at the peptide concentration of 50 × 10 −6 M (Figure S26g,h, Supporting Information). Compared with early apoptotic cells (Annexin positive only), the percentage of late apoptotic cells (both Annexin and PI positive) in A9-3 was much higher than that of free peptide, implying the different apoptosis process. Meanwhile, 100 × 10 −6 M Pep9 and 12 × 10 −6 M A9-3 induced the similar percentage of dead cells, illustrating the effective antitumor ability of PPCs. The enhanced anticancer effect of PPCs could be attributed to the effi cient entrance into cells through endocytosis pathway (Figure S27, Supporting Information). [ 25 ] To evaluate the biocompatibility of PPCs, the cytotoxicity of A9-3 nanoparticle to normal cells was investigated, and there was no signifi cant toxicity to L929 and HEK 293 cells at the peptide concentration of 50 × 10 −6 M (Figure S28, Supporting Information). In addition, the size changes in the PPC ( A9-3 ) nanoparticles in PBS solution and 10% serum were evaluated by DLS (Figure S29, Supporting Information). The diameters of nanoparticles exhibited little change in 24 h, proving the good incubation stability of nanoparticles. Moreover, there was no thrombin overexpression in plasma of mice after treatment with A9-3 (Figure S30, Supporting Information). We also observed the morphology of whole blood cells, proving that A9-3 did not induce the aggregation of platelet cells or red blood cells (Figure S31, Supporting Information). All these results indicated that PPC nanoparticles could not cause blood coagulation at the suitable injection dose. Therefore, the PPC nanoparticles are safe and suitable for intravenous injection in vivo with long circulation stability.\nThe tumor targetability and antitumor effi cacy of A9-3 nanoparticles were evaluated in U87 cell xenografted tumor nude mice model. All animal experiments were performed complying with the NIH guidelines for the care and use of laboratory animals of Peking University Animal Study Committee’s requirements and according to the protocol approved by the Institutional Animal Care. Cy5 labeled A9-3 nanoparticles were injected into U87 tumor-bearing nude mice through the tail vein. Strong fl uorescent signals around tumor were observed after 4 h injection (Figure S32, Supporting Information), indicating the specifi c tumor targeting of A9-3 nanoparticles. The biodistribution of A9-3 nanoparticles in mice was further evaluated by ex vivo experiments. As shown in Figure 3 c, the tumor exhibited stronger signal than other harvested organs, i.e., spleen, lung, heart, and kidney. To test the therapeutic activity of A9-3 nanoparticles, tumor-bearing mice were injected with A9-3 nanoparticles, and PBS, Pep9 , and A0 were used as control groups. The tumors treated with A9-3 nanoparticles increased more slowly than that of Pep9 (Figure 3 d). It was reasonable that the free peptides were degraded and removed from body quickly, and hence few KLAK could play a role in the tumor treatment. However, nanoscaled PPCs could specifi cally cumulate into the tumor site by enhanced permeability and retention (EPR) effect, exhibiting effective antitumor ability in vivo. Furthermore, the body weight of the mice treated with A9-3 nanoparticles revealed slight increase from 18.6 to 20.6 g, proving little toxicity of PPCs (Figure 3 e). The\nAdv. Mater. 2016, 28, 1859–1867\n1865wileyonlinelibrary.com© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nC O M M U N IC A TIO N\nAdv. Mater. 2016, 28, 1859–1867\nFigure 3. In vitro and in vivo evaluation of tumor treatment effi cacy of PPC nanoparticles. a) Comparison of mitochondrial membrane potentials (JC-1 assay) in U87 cells after incubation with Pep9 (free peptide RGD:KLAK = 2:8), A0 and A9-3 for 12 h with peptide concentration at 100 × 10 −6 M (RGD:KLAK = 2:8). b) Apoptosis analysis of Pep9 , A0 , and A9-3 in U87 cells were determined using annexin V-FITC/propidium iodide double staining after 24 h treatments. c) Quantitative analysis for the biodistribution of A9-3 nanoparticles in major organs 4 h post-injection to mice. Mice treated with PBS were regarded as the control group. Each column represented the mean value ( n = 3). d) Tumor volume changes after intravenous injection of PBS, Pep9 , A0 , and A9-3 in U87 tumor-bearing nude mice. Asterisks (*) denoted statistical signifi cance; * p < 0.05. e) Body weight changes of the four groups over the course of treatments. Values were expressed as means ± S.D ( n = 5). f) Representative images of the lung, liver, spleen, kidney, and heart sections (H&E staining) of mice treated with PBS (top) and A9-3 (bottom).\n1866 wileyonlinelibrary.com © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nC O\nM M\nU N\nIC A TI\nO N\nAdv. Mater. 2016, 28, 1859–1867\nsystemic toxicity of the A9-3 nanoparticles was further investigated by histopathology and hematology assays (Figure 3 f and Table S9, Supporting Information). There were no signifi cant differences in pathological signs between the mice treated with PPCs and the untreated control group. The mice treated with A9-3 indicated no signifi cant changes in red blood cell, white blood cell, and platelet counts compared to the control group. Furthermore, the levels of aminotransferases (ALT and AST) were within the normal ranges, showing that the liver functions were normal. Therefore, the hit PPC nanoparticle by screening exhibited signifi cant tumor suppression effect and no obvious toxic side effect.\nIn summary, we have fi rst developed a PPC synthesis and in situ screening strategy. The high-yield, bio-friendly chemistry, and mild reaction conditions fabricate the combinatorial synthesis and screening of therapeutic peptide nanomaterials. The PPCs could self-assemble into nanoparticles in the reaction process and were directly used for cytotoxicity assay without further purifi cation. This strategy fabricated investigating structure–function relationships of PPC library, and PPCs with optimal structures were prepared according to the guidelines. The reliability and scalability of this strategy were proved by enhanced cancer therapeutic effi cacy in vitro and in vivo. Therefore, the facile approach opened an avenue for rapid synthesis and screening of peptide nanomaterials. By further developing this synthesis and screening approach to incorporate other functional peptides and stimuli sensitive spacers, novel peptide nanomaterials may be found, which have broad application in disease diagnosis and therapy.\nSupporting Information Supporting Information is available from the Wiley Online Library or from the author."
    }, {
      "heading" : "Acknowledgements",
      "text" : "Z.-Y.Q. and Y.-X.L. contributed equally to this work. This work was supported by National Natural Science Foundation of China (21304023, 21374026, and 51303036), the National Basic Research Program of China (973 Program, 2013CB932701), and the 100-Talent Program of the Chinese Academy of Sciences.\nReceived: September 16, 2015 Revised: November 18, 2015\nPublished online: December 23, 2015\n[1] a) N. Ye , X. Zhang , M. Miao , X. Fan , Y. Zheng , D. Xu , J. Wang , L. Zhou , D. Wang , Y. Gao , Y. Wang , W. Shi , P. Ji , D. Li , Z. Guan , C. Shao , Z. Zhuang , Z. Gao , J. Qi , F. Zhao , Nat. Commun. 2015 , 6 , 6986 ; b) S. Boddohi , M. J. Kipper , Adv. Mater. 2010 , 22 , 2998 . [2] a) R. M. Brosh Jr. , Nat. Rev. Cancer 2013 , 13 , 542 ; b) Z. Li , T. M. Rana , Nat. Rev. Drug Discovery 2014 , 13 , 622 ; c) F. Pu , J. Ren , X. Qu , Adv. Mater. 2014 , 26 , 5742 . [3] a) C. D. Fjell , J. A. Hiss , R. E. W. Hancock , G. Schneider , Nat. Rev. Drug Discovery 2012 , 11 , 37 ; b) E. Ruoslahti , Adv. Mater. 2012 , 24 , 3747 ; c) R. L. DiMarco , S. C. Heilshorn , Adv. Mater. 2012 , 24 , 3923 ; d) Z. Y. Ong , N. Wiradharma , Y. Y. Yang , Adv. Drug Delivery Rev.\n2014 , 78 , 28 ; e) K. Liu , R. Xing , C. Chen , G. Shen , L. Yan , Q. Zou , G. Ma , H. Möhwald , X. Yan , Angew. Chem., Int. Ed. 2015 , 54 , 500 . [4] a) R. E. Vandenbroucke , C. Libert , Nat. Rev. Drug Discovery 2014 , 13 , 904 ; b) W. H. Hudson , E. A. Ortlund , Nat. Rev. Mol. Cell Biol. 2014 , 15 , 749 ; c) F. Wang , Z. Liu , B. Wang , L. Feng , L. Liu , F. Lv , Y. Wang , S. Wang , Angew. Chem., Int. Ed. 2014 , 53 , 424 . [5] a) C. Haass , D. J. Selkoe , Nat. Rev. Mol. Cell Biol. 2007 , 8 , 101 ; b) A. M. Fernandez , T.-I. Aleman , Nat. Rev. Neurosci. 2012 , 13 , 225 ; c) A. A. Kaspar , J. M. Reichert , Drug Discovery Today 2013 , 18 , 807 ; d) X.-X. Zhang , H. S. Eden , X. Chen , J. Controlled Release 2012 , 159 , 2 . [6] a) K. C. Mulder , L. A. Lima , V. J. Miranda , S. C. Dias , O. L. Franco , Front. Microbiol. 2013 , 4 , 321 ; b) Z. Antosova , M. Mackova , V. Kral , T. Macek , Trends Biotechnol. 2009 , 27 , 628 . [7] a) M. Góngora-Benítez , T.-J. Puche , F. Albericio , Chem. Rev. 2013 , 114 , 901 ; b) I. Cobo , M. Li , B. S. Sumerlin , S. Perrier , Nat. Mater. 2015 , 14 , 143 . [8] a) A. Tyagi , P. Kapoor , R. Kumar , K. Chaudhary , A. Gautam , G. P. S. Raghava , Sci. Rep. 2013 , 3 , 2984 ; b) M. Cieslewicz , J. Tang , J. L. Yu , H. Cao , M. Zavaljevski , K. Motoyama , A. Lieber , E. W. Raines , S. H. Pun , Proc. Natl. Acad. Sci. USA 2013 , 110 , 15919 . [9] a) S. M. Standley , D. J. Toft , H. Cheng , S. Soukasene , J. Chen , S. M. Raja , V. Band , H. Band , V. L. Cryns , S. I. Stupp , Cancer Res. 2010 , 70 , 3020 ; b) M. Elsabahy , K. L. Wooley , Acc. Chem. Res. 2015 , 48 , 1620 ; c) Q. Zou , K. Liu , M. Abbas , X. Yan , Adv. Mater. 2015 , 10.1002/adma.201502454 . [10] a) B. P. Shah , N. Pasquale , G. De , T. Tan , J. Ma , K.-B. Lee , ACS Nano 2014 , 8 , 9379 ; b) L. Agemy , F.-D. Morvinski , V. R. Kotamraju , L. Roth , K. N. Sugahara , O. M. Girard , R. F. Mattrey , I. M. Verma , E. Ruoslahti , Proc. Natl. Acad. Sci. USA 2011 , 108 , 17450 . [11] a) Y. Zhao , F. Sakai , L. Su , Y. Liu , K. Wei , G. Chen , M. Jiang , Adv. Mater. 2013 , 25 , 5215 ; b) H. Tian , Z. Tang , X. Zhuang , X. Chen , X. Jing , Prog. Polym. Sci. 2012 , 37 , 237 ; c) E. F. Banwell , E. S. Abelardo , D. J. Adams , M. A. Birchall , A. Corrigan , A. M. Donald , M. Kirkland , L. C. Serpell , M. F. Butler , D. N. Woolfson , Nat. Mater. 2009 , 8 , 596 . [12] H. Lu , J. Wang , Y. G. Bai , J. W. Lang , S. Y. Liu , Y. Lin , J. J. Cheng , Nat. Commun. 2011 , 2 , 206 . [13] a) L. Setton , Nat. Mater. 2008 , 7 , 172 ; b) A. W. Du , M. H. Stenzel , Biomacromolecules 2014 , 15 , 1097 . [14] a) L. Wang , L.-L. Li , Y.-S. Fan , H. Wang , Adv. Mater. 2013 , 25 , 3888 ; b) D. Zhang , G.-B. Qi , Y.-X. Zhao , S.-L. Qiao , C. Yang , H. Wang , Adv. Mater. 2015 , 27 , 6125 . [15] a) Y. Wang , Y.-X. Lin , Z.-Y. Qiao , H.-W. An , S.-L. Qiao , L. Wang , R. P. Y. J. Rajapaksha , H. Wang , Adv. Mater. 2015 , 27 , 2627 ; b) Y. Liu , D. Zhang , Z.-Y. Qiao , G.-B. Qi , X.-J. Liang , X.-G. Chen , H. Wang , Adv. Mater. 2015 , 27 , 5034 . [16] a) A. L. Hook , C.-Y. Chang , J. Yang , J. Luckett , A. Cockayne , S. Atkinson , Y. Mei , R. Bayston , D. J. Irvine , R. Langer , D. G. Anderson , P. Williams , M. C. Davies , M. R. Alexander , Nat. Biotechnol. 2012 , 30 , 868 ; b) D. J. Siegwart , K. A. Whitehead , L. Nuhn , G. Sahay , H. Cheng , S. Jiang , M. L. Ma , L.-A. Jean , A. Vegas , P. Fenton , C. G. Levins , K. T. Love , H. Lee , C. Cortez , S. P. Collins , Y. F. Li , J. Jang , W. Querbes , C. Zurenko , T. Novobrantseva , R. Langer , D. G. Anderson , Proc. Natl. Acad. Sci. USA 2011 , 108 , 12996 ; c) Y. Mei , K. Saha , S. R. Bogatyrev , J. Yang , A. L. Hook , Z. I. Kalcioglu , S. W. Cho , M. Mitalipova , N. Pyzocha , F. Rojas , K. J. Van Vliet , M. C. Davies , M. R. Alexander , R. Langer , R. Jaenisch , D. G. Anderson , Nat. Mater. 2010 , 9 , 768 ; d) J. J. Green , R. Langer , D. G. Anderson , Acc. Chem. Res. 2008 , 41 , 749 ; e) A. Akinc , A. Zumbuehl , M. Goldberg , E. S. Leshchiner , V. Busini , N. Hossain , S. A. Bacallado , D. N. Nguyen , J. Fuller , R. Alvarez , A. Borodovsky , T. Borland , R. Constien , A. de Fougerolles , J. R. Dorkin , K. N. Jayaprakash , M. Jayaraman , M. John , V. Koteliansky , M. Manoharan , L. Nechev , J. Qin , T. Racie , D. Raitcheva , K. G. Rajeev , D. W. Y. Sah , J. Soutschek , I. Toudjarska ,\n1867wileyonlinelibrary.com© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nC O M M U N IC A TIO N\nAdv. Mater. 2016, 28, 1859–1867\nH. P. Vornlocher , T. S. Zimmermann , R. Langer , D. G. Anderson , Nat. Biotechnol. 2008 , 26 , 561 . [17] D. M. Lynn , R. Langer , J. Am. Chem. Soc. 2000 , 122 , 10761 . [18] F. Danhier , Le A. Breton , V. Preat , Mol. Pharm. 2012 , 9 , 2961 . [19] a) J. C. Mai , Z. B. Mi , S. H. Kim , B. Ng , P. D. Robbins , Cancer Res.\n2001 , 61 , 7709 ; b) H. M. Ellerby , W. Arap , L. M. Ellerby , R. Kain , R. Andrusiak , G. Del Rio , S. Krajewski , C. R. Lombardo , R. Rao , E. Ruoslahti , D. E. Bredesen , R. Pasqualini , Nat. Med. 1999 , 5 , 1032 . [20] Q. Zhang , M. Li , C. Zhu , G. Nurumbetov , Z. Li , P. Wilson , K. Kempe , D. M. Haddleton , J. Am. Chem. Soc. 2015 , 137 , 9344 .\n[21] a) S. Salatin , S. M. Dizaj , A. Y. Khosroushahi , Cell Biol. Int. 2015 , 39 , 881 ; b) M. E. Davis , Z. Chen , D. M. Shin , Nat. Rev. Drug Discovery 2008 , 7 , 771 ; c) X. Duan , Y. Li , Small 2013 , 9 , 1521 . [22] D. H. Jo , J. H. Kim , T. G. Lee , J. H. Kim , Nanomed. Nanotechnol. Biol. Med. 2015 , 11 , 1603 . [23] W.-H. Chen , X.-D. Xu , G.-F. Luo , H.-Z. Jia , Q. Lei , S.-X. Cheng , R.-X. Zhuo , X.-Z. Zhang , Sci. Rep. 2013 , 3 , 3468 . [24] L. Zhu , T. Wang , F. Perche , A. Taigind , V. P. Torchilin , Proc. Natl. Acad. Sci. USA 2013 , 110 , 17047 . [25] Z.-Y. Qiao , C. Hou , D. Zhang , Y. Liu , Y.-X. Lin , H.-W. An , X.-J. Li , H. Wang , J. Mater. Chem. B 2015 , 3 , 2943 ."
    } ],
    "references" : [ ],
    "referenceMentions" : [ ],
    "year" : 2016,
    "abstractText" : "DOI: 10.1002/adma.201504564 procedures were not suitable for peptide nanomaterial synthesis, which may cause peptide denaturation and affect their biological properties. Furthermore, the present methods for PPCs synthesis focus on the post-modifi cation, [ 13b ] but there are few reports [ 7b ] about the immediate polymerization and selfassembly of peptide that is one of the most facile approaches for construction of peptide nanosystems. Therefore, a general and simple synthesis strategy is required for polymer-peptide based nanomaterial synthesis and screening. Here, we fi rst report a general strategy for facile synthesis and in situ screening of a library of self-assembled PPCs. For peptides with different reactive groups, various synthesis methods based on Michael-type addition were developed. The mild and effi cient reaction with nearly quantitative yields in aqueous solutions allowed the minimal loss of peptide activity and direct biological performance measurements without purifi cation. Targeting and therapeutic peptides as model functional peptides were copolymerized with a wide variety of spacers, to obtain a diverse library of PPCs with different chemical structures, which simultaneously self-assembled into nanoparticles in the reaction process. Subsequently, the in situ cell-based screening of PPCs was used to quickly assess the therapeutic performance of PPCs. Owing to the strategy that revealed the relationship between structural features of PPCs (peptide ratio, spacer length, degree of polymerization (DP), modifi cation degree (MD), etc.) and their functions, we can somewhat predictably design and prepare PPCs with desired properties. The enhanced tumor treatment effi cacies of PPCs compared with free peptides were verifi ed in vitro and in vivo. We envision that this synthesis and screening approach provides an avenue for rapid preparation and optimization of polymer-peptide nanomaterials for different purposes. In order to realize the polymerization of peptides, various synthesis methods based on Michael-type addition were developed. [ 17 ] For peptides without side amine groups, two approaches were explored for synthesis of PPCs. The one is to modify a glycine at N-terminal of peptide to obtain amine terminal peptide, and glycine and peptide GGG were used as model peptides (Schemes S1a and S2, Figures S1–S3, Supporting Information). Because glycine carries no substituents in α position, both protons in amine groups can react with diacrylate or bisacrylamide groups under the suitable conditions ( Scheme 1 a-i and Tables S1–S3, Supporting Information). The other one is modifying a cysteine in peptide chains (called amine/thiol peptide), and peptide glutathione (GSH) was Synthetic biomaterials based on the bioactive molecules, such as polysaccharides, [ 1 ] nucleic acids, [ 2 ] peptides, [ 3 ] and proteins, [ 4 ]",
    "creator" : null
  }
}